European Biotech Acquisition registered with the SEC to offer 10 million units at $10 each.
The new SPAC in the filing said it plans to pursue opportunities in the life sciences industry in Europe.
European Biotech is led by CEO Eduardo Bravo Fernandez de Araoz, who from July-December 2020 was interim CEO of OncoDNA, a cancer theranostic company. He was previously CEO of Nordic Nanovector, a radiopharmaceutical company and CEO of TiGenix, a cell therapy company. CFO Koen Sintnicolaas, who until December was business controller of LSP, an affiliate of the SPAC’s sponsor and one of Europe’s largest healthcare investment firms.
The SPAC expects to list on the Nasdaq but has not yet chosen a ticker symbol. Read more.
